Literature DB >> 6721989

Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

M V Rudorfer, E A Lane, W H Chang, M D Zhang, W Z Potter.   

Abstract

In order to better define the role of pharmacokinetic variation in reported cross-ethnic differences in dosing patterns of some psychoactive drugs, single dose kinetics of the tricyclic antidepressant desipramine (DMI) were studied in 14 Chinese and 16 Caucasian healthy volunteers. DMI and 2-OH-DMI concentrations were assayed with h.p.l.c. in serial plasma and 24 h urine samples over 5 days following an oral 100 mg dose of DMI. Mean total clearance of DMI ( CLDMI ) from plasma was significantly (P less than 0.05) higher in the Caucasians (123 +/- 57 l/h) than in the Chinese (73.5 +/- 38.8 l/h). There was no significant difference in the apparent clearance of DMI by hydroxylation, fraction of dose metabolized to the hydroxy metabolite, DMI t1/2 or plasma protein binding between the two groups. Trimodal distribution of CLDMI was found, with 4/14 (29%) Chinese demonstrating slow CL (less than 33 l/h) and 4/16 (25%) Caucasians rapid CL (greater than 195 l/h). Correcting CL values for the greater mean weight of the Caucasians did not alter the pattern of distribution. CLDMI did not correlate with body weight. Although environmental factors cannot be ruled out, these results are consistent with genetically based differences in hepatic metabolism, probably affecting pathways in addition to hydroxylation, and suggest that 30% of Orientals would be at risk for toxicity from routine doses of tricyclics or similarly metabolized drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721989      PMCID: PMC1463412          DOI: 10.1111/j.1365-2125.1984.tb02368.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Comparative analysis of the action of butyrylperazine at Manhattan State Hospital and the University Psychiatric Clinic at Erlangen.

Authors:  H C DENBER; D BENTE; P RAJOTTE
Journal:  Am J Psychiatry       Date:  1962-09       Impact factor: 18.112

2.  Differences in the effects of clomipramine on English and Asian volunteers. Preliminary report on a pilot study.

Authors:  J J Allen; P H Rack; K S Vaddadi
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites.

Authors:  T A Sutfin; W J Jusko
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

4.  Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations.

Authors:  M Asberg; D A Evans; F Sjöqvist
Journal:  J Med Genet       Date:  1971-06       Impact factor: 6.318

5.  Metabolism of 14C-imipramine. II. Urinary metabolites in man.

Authors:  J L Crammer; B Scott; B Rolfe
Journal:  Psychopharmacologia       Date:  1969

6.  High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.

Authors:  G Alvan; C von Bahr; P Seidemann; F Sjöqvist
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

7.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds.

Authors:  W Hammer; F Sjöqvist
Journal:  Life Sci       Date:  1967-09-01       Impact factor: 5.037

8.  Active metabolites of imipramine and desipramine in man.

Authors:  W Z Potter; H M Calil; T A Sutfin; A P Zavadil; W J Jusko; J Rapoport; F K Goodwin
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

9.  Altered hydroxydesipramine concentrations in elderly depressed patients.

Authors:  I Kitanaka; R J Ross; N R Cutler; A P Zavadil; W Z Potter
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

10.  Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy.

Authors:  B Alexanderson; D A Evans; F Sjöqvist
Journal:  Br Med J       Date:  1969-12-27
View more
  18 in total

1.  Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.

Authors:  M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

2.  Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese.

Authors:  Guo Yu; Hong-Hao Zhou; Qing-Shan Zheng; Guo-Fu Li
Journal:  Eur J Clin Pharmacol       Date:  2018-12-19       Impact factor: 2.953

3.  Tricyclic Antidepressants: What to Choose and Which Dose?

Authors:  Daniel Keszthelyi; Ad A Masclee
Journal:  Am J Gastroenterol       Date:  2016-07       Impact factor: 10.864

Review 4.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

5.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

6.  Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers.

Authors:  K M Lin; J K Lau; R Smith; P Phillips; E Antal; R E Poland
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Ethnicity and psychopharmacology.

Authors:  K M Lin; R E Poland; I M Lesser
Journal:  Cult Med Psychiatry       Date:  1986-06

8.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

Review 9.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 10.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.